Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Antares Pharma Cmn (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 500,535
  • Shares Outstanding, K 155,930
  • Annual Sales, $ 52,220 K
  • Annual Income, $ -24,340 K
  • 36-Month Beta 0.67
  • Price/Sales 8.99
  • Price/Cash Flow 0.00
  • Price/Book 11.31

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +36.60%
on 05/31/17
3.24 -0.93%
on 06/23/17
+0.68 (+26.88%)
since 05/23/17
3-Month
2.35 +36.60%
on 05/31/17
3.24 -0.93%
on 06/23/17
+0.44 (+15.88%)
since 03/23/17
52-Week
0.92 +248.91%
on 06/24/16
3.24 -0.93%
on 06/23/17
+2.20 (+217.82%)
since 06/23/16

Most Recent Stories

More News
BUYINS.NET: ATRS SqueezeTrigger Price is $3.14. There is $8,329,731 That Short Sellers Still Need To Cover.

BUYINS.NET / www.buyins.net is monitoring Antares Pharma Inc. (NASDAQ:ATRS) in real time and just received an alert that ATRS is crossing above its primary SqueezeTrigger Price, the price that a short...

ATRS : 3.21 (+6.64%)
Research and Markets - Global Needle-Free Drug Delivery Market to Grow at a CAGR of 10.3% by 2021: Key Vendors are Endo Pharmaceuticals, Antares Pharma, Inovio Pharmaceuticals, Valeritas & PharmaJet

DUBLIN, June 20, 2017 /PRNewswire/ --

ATRS : 3.21 (+6.64%)
INO : 8.20 (+1.49%)
Research and Markets - Global Needle-Free Drug Delivery Market to Grow at a CAGR of 10.3% by 2021: Key Vendors are Endo Pharmaceuticals, Antares Pharma, Inovio Pharmaceuticals, Valeritas & PharmaJet

Research and Markets has announced the addition of the "Global Needle-Free Drug Delivery Market 2017-2021" report to their offering.

ATRS : 3.21 (+6.64%)
INO : 8.20 (+1.49%)
Antares Pharma Announces Debt Financing From Hercules Capital

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that it has entered into a loan and security agreement for a term loan of up to $35 million, with Hercules Capital, Inc. (NYSE:HTGC) ("Hercules"), a leader...

HTGC : 13.30 (+0.53%)
ATRS : 3.21 (+6.64%)
Antares Pharma to Present at the Jefferies 2017 Healthcare Conference

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2017 Healthcare Conference on Thursday, June 8, 2017 at 10:00...

ATRS : 3.21 (+6.64%)
Research Reports Coverage on Medical Supplies Stocks -- Antares Pharma, Becton, Dickinson, Integra LifeSciences, and Waters

On Thursday, the NASDAQ Composite ended the day at 6,075.34, up 0.05%; the Dow Jones Industrial Average edged 0.03% lower, to finish at 20,951.47; and the S&P 500 closed at 2,389.52, slightly gaining 0.06%....

BDX : 195.15 (+0.05%)
IART : 54.34 (+0.98%)
ATRS : 3.21 (+6.64%)
WAT : 185.47 (+0.31%)
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference on Thursday,...

ATRS : 3.21 (+6.64%)
DB : 16.64 (-0.60%)
Antares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Annual Meeting

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that data from the 52-week pharmacokinetics and safety phase 3 study of subcutaneous testosterone enanthate delivered through the QuickShot auto injector...

ATRS : 3.21 (+6.64%)
Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results

2016 Results Driven by Continued Growth in Product Sales and Significant Progress in Pipeline Programs

ATRS : 3.21 (+6.64%)
Antares Pharma to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Webcast and Conference Call

Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its fourth quarter and full year 2016 financial results and recent operating progress before the market opens on Tuesday, March 14, 2017....

ATRS : 3.21 (+6.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Support & Resistance

2nd Resistance Point 3.34
1st Resistance Point 3.28
Last Price 3.21
1st Support Level 3.11
2nd Support Level 3.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.